The strategic transaction reduces BYSI's cash burn for DUBLIN-4 but the concurrent ATM offering creates near-term dilution overhang. Watch for DUBLIN-4 interim analysis (221 PFS events) as the next major catalyst. The Equity Clawback provision provides downside protection if China enrollment lags. Fast Track designation is a positive regulatory signal but does not guarantee approval.
Price Chart
Executive Summary
BeyondSpring entered into a definitive agreement to sell its wholly owned subsidiary (which indirectly holds a 57.97% stake in its Chinese operating entity, Bulin) to Biolin Investment Limited in exchange for Biolin funding the China portion of the global Phase 3 DUBLIN-4 trial of Plinabulin + docetaxel in post-ICI non-squamous NSCLC. The company also simultaneously filed an at-the-market (ATM) offering of up to 9.2M shares (up to ~$11.9M) via Citizens JMP. The FDA granted Fast Track designation for the same Plinabulin combination. The transaction is non-dilutive to BYSI shareholders but the concurrent ATM offering introduces near-term dilution risk.
Key Financial Metrics
Key Facts
- BeyondSpring sold BeyondSpring Ltd. (indirectly holding 57.97% of Bulin) to Biolin Investment Limited for non-cash consideration — Biolin will fund the China portion of DUBLIN-4 (expected ~221 of 442 patients).
- FDA granted Fast Track designation for Plinabulin + docetaxel in post-ICI non-squamous NSCLC (the DUBLIN-4 population).
- Concurrent ATM offering of up to 9.2M ordinary shares (up to ~$11.9M at $0.7772/share) via Citizens JMP Securities, filed same day.
- DUBLIN-4 has a prespecified interim analysis at 221 PFS events; China enrollment expected within 3 years.
- BeyondSpring retains global rights to Plinabulin outside Greater China.
- If China enrollment target (221-265 patients) is not met within 3 years, Biolin must return a pro-rata portion of the equity (Equity Clawback).
Financial Impact
No cash consideration received; non-cash deal valued at the cost of funding ~221-patient China trial. ATM offering up to ~$11.9M gross proceeds at 3% commission. No revenue or EPS figures in filing.
Risk Factors
- ATM offering dilutes existing shareholders by up to ~26% (9.2M shares vs ~35.8M shares outstanding).
- China enrollment may not meet target within 3 years, triggering Equity Clawback.
- DUBLIN-4 interim analysis may not meet statistical significance.
- Regulatory and data-transfer risks for China-generated clinical data in global filing.
- BYSI received Nasdaq deficiency notice (Sept 17, 2026) — delisting risk if not cured.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-006273 |
| Exhibit: exh_11.htm | 0001171843-26-006273 |
| Exhibit: exh_51.htm | 0001171843-26-006273 |
| Exhibit: exh_991.htm | 0001171843-26-006273 |
| Document: f8k_092826.htm | 0001171843-26-006273 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 8-K | $0.6450 $0.5870 | ▼ −8.99% | ▼ −8.01% | $0.4620 (−28.37%) |
Oct 2, 2026 25d ago | 8-K | $0.7860 $0.6155 | ▲ +21.69% | ▲ +22.11% | $0.4620 (+41.22%) |
Sep 29, 2026 28d ago | 8-K | $0.7733 $0.6923 | ▼ −10.47% | ▼ −12.42% | $0.4620 (−40.26%) |
Sep 29, 2026 28d ago | 424B5 | $0.7733 $0.6923 | ▲ +10.47% | ▲ +12.42% | $0.4620 (+40.26%) |
Sep 18, 2026 5w ago | 8-K | $0.7400 $1.12 | ▼ −51.35% | ▼ −52.37% | $0.4620 (+37.57%) |
Sep 3, 2026 7w ago | DEFA14A | $0.6181 $0.7600 | ▲ +22.96% | ▲ +24.17% | $0.4620 (−25.25%) |
Aug 14, 2026 10w ago | 8-K | $0.7115 $0.7092 | ▼ −0.32% | ▲ +0.87% | $0.4620 (−35.07%) |
Aug 14, 2026 10w ago | Press Release | $0.7115 $0.7092 | ▼ −0.32% | ▲ +0.87% | $0.4620 (−35.07%) |
Jun 4, 2026 20w ago | 8-K | $1.71 $1.65 | ▼ −3.51% | ▼ −0.96% | $0.4620 (−72.98%) |
Jun 2, 2026 21w ago | Press Release | $1.70 $1.72 | ▲ +1.18% | ▲ +4.14% | $0.4620 (−72.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers